The pharmacology of esomeprazole and its role in gastric acid related diseases

Bibliography

• Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-51
   PubMed Web of Science ®Google Scholar
• McKeage K, Blick SKA, Croxtall JD, et al. Esomeprazole a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008;68(11):1571-607
   PubMed Web of Science ®Google Scholar
• Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in management of acid-related disorders. Drugs 2002;62(10):1503-38
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2-8
   PubMed Web of Science ®Google Scholar
• Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Clin Pharmacol Toxicol 2004;94:106-11
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors – comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009;65:19-31
   PubMed Web of Science ®Google Scholar
• Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2007;42:157-64
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-745
   PubMed Web of Science ®Google Scholar
• Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005;22(Suppl 3):20-4
   PubMed Web of Science ®Google Scholar
• Andersson T, Rohss K, Bredberg E, et al. Pharmocokinetics and pharmacodynamics of esomeprazole, the s-isomer of omeprazole. Aliment Pharmacol Ther 2001;15:1563-9
   PubMed Web of Science ®Google Scholar
• Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665-70
   PubMed Web of Science ®Google Scholar
• Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-7
   PubMed Web of Science ®Google Scholar
• Sostek M, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol 64(3):386-90
   PubMed Web of Science ®Google Scholar
• Bladh N, Blychert E, Johansson K, et al. A new esomeprazole packet (Sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. Clin Ther 29(4):640-9
   PubMed Web of Science ®Google Scholar
• Omari T, Davidson G, Bondarov P, et al. Pharmacokinetics and Acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. JPGN 2007;45:530-7
   Web of Science ®Google Scholar
• Zhao J, Jianguo L, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28(11):1868-76
   PubMed Web of Science ®Google Scholar
• Jianguo L, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28(3):419-27
   PubMed Web of Science ®Google Scholar
• Abelo A, Andersson T, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000;28(8):966-72
   PubMed Web of Science ®Google Scholar
• Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005;78:627-34
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40(6):411-26
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetic considerations in the eradication of helicobacter pylori. Clin Pharmacokinet 2000;38(3):243-70
   PubMed Web of Science ®Google Scholar
• Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001;40(2):145-50
   PubMed Web of Science ®Google Scholar
• Naesdal J, Andersson T, Bodemar G, et al. Pharmacokinetics of [14C] omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986;40(3):344-51
   PubMed Web of Science ®Google Scholar
• Sjovall H, Bjornsson E, Holmberg J, et al. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 2002;14(5):491-6
   PubMed Web of Science ®Google Scholar
• Miner P, Katz PO, Chen Y, et al. Gastric acid control with Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole and Rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98(2):2616-20
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Achim A, Riddermann T, et al. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving ‘complete remission’ in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007;25(12):1461-9
   PubMed Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97(3):575-83
   PubMed Web of Science ®Google Scholar
• Fennerty MB, Johanson JF, Hwang C, et al. Efficacy of esomeprazole 40mg vs. lansoprazole 30mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005;21(4):455-63
   PubMed Web of Science ®Google Scholar
• Gillessen A, Beil W, Modlin IM, et al. 40mg pantoprazole and 40mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004;38(4):332-40
   PubMed Web of Science ®Google Scholar
• Howden CW, Ballard II ED, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002;22(2):99-109
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40mg versus pantoprazole 40mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21(6):739-46
   PubMed Web of Science ®Google Scholar
• Lightdale CJ, Schmitt C, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20mg) and standard-dose omeprazole (20mg) in patients with erosive esophagitis. Dig Dis Sci 2006;51(5):852-7
   PubMed Web of Science ®Google Scholar
• Schmitt C, Lightdale CJ, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40mg) and omeprazole (20mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006;51(5):844-50
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14(10):1249-58
   PubMed Web of Science ®Google Scholar
• Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 24:743-50
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006;4:1452-8
   PubMed Web of Science ®Google Scholar
• Sheu BS, Chang WL, Cheng HC, et al. Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole. Am J Gastroenterol 2008;103:2209-14
   PubMed Web of Science ®Google Scholar
• De Vault KR, Johanson JF, Johnson DA, et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006;4(7):852-9
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20mg and lansoprazole 15mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacol Ther 2003;17(3):333-41
   PubMed Web of Science ®Google Scholar
• Johnson DA, Banjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96(1):27-34
   PubMed Web of Science ®Google Scholar
• Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15(7):927-35
   PubMed Web of Science ®Google Scholar
• Goh KL, Benamouzig R, Sander P, et al. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial – the EMANCIPATE study. Eur J Gastroenterol Hepatol 19:205-11
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20mg vs. pantoprazole 20mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005;22(9):803-11
   PubMed Web of Science ®Google Scholar
• Galmiche JP. EMANCIPATE study: drawing conclusions may be difficult in the absence of fundamental information. Eur J Gastroenterol Hepatol 2008;20(2):151-2
   PubMed Web of Science ®Google Scholar
• Labenz J. EMANCIPATE versus EXPO: different results can be explained by differing study designs. Eur J Gastroenterol Hepatol 2008;20(2):152
   PubMed Web of Science ®Google Scholar
• Maton PN, Vakil NB, Levine JG, et al. Esomeprazole Study Investigators. Safety and efficacy of long-term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001;24:625-35
   PubMed Web of Science ®Google Scholar
• Sjostedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005;22(3):183-91
   PubMed Web of Science ®Google Scholar
• Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic anti-reflux surgery to esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut [Epub 2008 May]
   Google Scholar
• Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic antireflux surgery with Esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008;57:1207-13
   PubMed Web of Science ®Google Scholar
• Attwood SE, Lundell L, Hatlebakk JG, et al. Medical or surgical management of GERD patients with Barrett's Esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 2008;12:1646-55
   PubMed Web of Science ®Google Scholar
• Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004;20(4):413-21
   PubMed Web of Science ®Google Scholar
• Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive esophagitis. Aliment Pharmacol Ther 2003;18(9):875-82
   PubMed Web of Science ®Google Scholar
• Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20mg on-demand is more acceptable to patients than continuous lansoprazole 15mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004;20(6):657-65
   PubMed Web of Science ®Google Scholar
• Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14(8):857-63
   PubMed Web of Science ®Google Scholar
• Talley NJ, Lauritsen K, Tuntunri-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of on demand therapy for 6 months. Aliment Pharmacol Ther 2001;15(3):347-54
   PubMed Web of Science ®Google Scholar
• Fock KM, Teo EK, Ang TL, et al. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease a randomized, double-blind study in urban Asia. World J Gastroenterol 2005;11:3091-8
   PubMed Web of Science ®Google Scholar
• Pace F, Tonini M, Pallota S, et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’. Aliment Pharmacol Ther 2007;26:195-204
   PubMedGoogle Scholar
• Metz DC, Inadomi JM, Howden CW, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 2007;102:642-53
   PubMed Web of Science ®Google Scholar
• The American Lung Association Asthma Clinical Research Centers. Efficacy of Esomeprazole for treatment of poorly controlled asthma. N Eng J Med 2009;360(15):1487-99
   PubMed Web of Science ®Google Scholar
• Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001;13(12):1457-65
   PubMed Web of Science ®Google Scholar
• Wu IC, Wu DC, Hsu PI, et al. Rabeprazole versus esomeprazole based eradication regiments for H. pylori infection. Helicobacter 2007;12(6):633-7
   PubMed Web of Science ®Google Scholar
• Veldhuyzen van Zanten S, Lauritsen K, Delchier J-C, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14(12):1605-11
   PubMed Web of Science ®Google Scholar
• Veldhuyzen van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17(11):1381-7
   PubMed Web of Science ®Google Scholar
• Laine L, Fennerty B, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000;95(12):3393-8
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lai KH, Wu CJ, et al. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection. Eur J Clin Invest 2007;37(9):724-30
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100(11):2387-92
   PubMed Web of Science ®Google Scholar
• Subei IM, Cardona HJ, Bachelet E, et al. One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healing in Helicobacter pylori-positive patients. Dig Dis Sci 2007;52(6):1505-12
   PubMed Web of Science ®Google Scholar
• Tulassay Z, Stolte M, Sjolund M, et al. Effect of esomeprazole triple therapy on Helicobacter pylori eradication rates, gastric ulcer healing, and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol 2008;20(6):526-36
   PubMed Web of Science ®Google Scholar
• Sung JJY, Barkun A, Kuipers E, et al. Intravenous Esomeprazole for prevention of recurrent peptic ulcer bleeding. Ann Intern Med 2009;150:455-64
   PubMed Web of Science ®Google Scholar
• Morgner A, Michlke S, Labenz J. Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opin Phamacother 2007;8(7):975-88
   PubMed Web of Science ®Google Scholar
• Laine L. The gastrointestinal effects of nonselective NSAIDS and COX-2-selective inhibitors. Semin. Arthritis Rheum 2002;32:25-32
   Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007;26(8):1101-11
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005;100(12):2650-7
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hallas J, Lauritsen JM, et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996;31:126-30
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101(4):701-10
   PubMed Web of Science ®Google Scholar
• Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005;100(5):1028-36
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Talley NJ, Scheiman JM, et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther 2007;9(1):R17
   PubMed Web of Science ®Google Scholar
• Yeomans N, Lanas A, Labenz J, et al. Prevention of low dose aspirin-associated gastroduodenal ulcers and upper gastrointestinal symptoms in patients receiving esomeprazole 20mg per day [abstract no. P2307]. Eur Heart J 2006;27(Suppl 1):382
   PubMedGoogle Scholar
• Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102(12):2648-54
   PubMed Web of Science ®Google Scholar
• Siller-Matula J, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5
   PubMed Web of Science ®Google Scholar
• Hassan-Alin M, Naesdal J, Nilsson-Pieschel C, et al. Lack of Pharmacokinetic interaction between esomeprazole and the nonsteroidal anti-inflammatory drugs naproxen and rofecoxib in healthy subjects. Clin Drug Investig 2005;25(11):731-40
   PubMed Web of Science ®Google Scholar
• Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008;47(2):75-89
   PubMed Web of Science ®Google Scholar
• McCabe SM, Smith PF, Ma Q, et al. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol 2007;3(2):197-207
   PubMed Web of Science ®Google Scholar
• Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006;42(1):61-7
   PubMed Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97(3):575-83
   PubMed Web of Science ®Google Scholar
• Genta RM, Rindi G, Fiocca R, et al. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol 2003;98:1257-65
   PubMed Web of Science ®Google Scholar
• US FDA Center for Drug Evaluation and Research. Early communication about an ongoing safety review: omeprazole (Prilosec) and esomeprazole (Nexium) [online]. Available from: http://www.fda.gov/CDER/Drug/early_comm/omeprazole_esomeprazole.htm [Accessed 31 March 2009]
   Google Scholar
• Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors. Eur J Clin Pharmacol 2006;62:473-9
   PubMed Web of Science ®Google Scholar
• Caboni S, Gunera-Saad N, Ktiouet-Abassi S, et al. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs. Allergy 2007;62:1342-3
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, et al. Long-term pump inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947-53
   PubMed Web of Science ®Google Scholar
• Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-8
   PubMed Web of Science ®Google Scholar
• Martin de Argila C. Safety of potent gastric acid inhibition. Drugs 2005;65(Suppl 1):97-104
   PubMed Web of Science ®Google Scholar
• Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008;31(7):627-36
   PubMed Web of Science ®Google Scholar
• Johnson D. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003;4(2):253-64
   PubMed Web of Science ®Google Scholar
• Kalaitzakis E, Bjornsson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manage 2007;3(4):653-63
   PubMedGoogle Scholar